Counterweight Ventures LLC Increases Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Counterweight Ventures LLC grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 591.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,384 shares of the biotechnology company's stock after buying an additional 79,884 shares during the quarter. Counterweight Ventures LLC's holdings in BioCryst Pharmaceuticals were worth $710,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. CWM LLC lifted its holdings in BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company's stock worth $35,000 after buying an additional 3,772 shares in the last quarter. Signaturefd LLC grew its stake in BioCryst Pharmaceuticals by 560.5% during the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 5,599 shares in the last quarter. Seven Eight Capital LP purchased a new stake in BioCryst Pharmaceuticals during the 1st quarter worth about $57,000. Mirae Asset Global Investments Co. Ltd. raised its position in BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 1,322 shares in the last quarter. Finally, Natixis boosted its stake in shares of BioCryst Pharmaceuticals by 400.6% in the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company's stock valued at $59,000 after buying an additional 9,350 shares during the period. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Up 2.1 %

BCRX traded up $0.15 on Tuesday, reaching $7.21. The company had a trading volume of 1,590,943 shares, compared to its average volume of 2,936,948. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $8.88. The stock has a market capitalization of $1.49 billion, a PE ratio of -11.82 and a beta of 1.89. The stock has a 50-day moving average price of $7.68 and a 200-day moving average price of $7.20.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts' consensus estimates of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. The firm's revenue for the quarter was up 35.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.19) EPS. As a group, analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Needham & Company LLC restated a "buy" rating and issued a $14.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. JMP Securities boosted their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a "market outperform" rating in a research note on Tuesday, August 6th. HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Finally, StockNews.com raised BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday, August 6th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $14.67.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.